Global Guillain-Barre Syndrome Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Guillain-Barre Syndrome treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Akari Therapeutics Plc, Annexon Inc, Complement Pharma BV, CuraVac Inc, Hansa Medical AB and others.
A Significant contribution to the Guillain-Barre Syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Guillain-Barre Syndrome pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Guillain-Barre Syndrome condition and increased access to investments is encouraging growth of Guillain-Barre Syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Guillain-Barre Syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Guillain-Barre Syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Guillain-Barre Syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Guillain-Barre Syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Guillain-Barre Syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Guillain-Barre Syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Guillain-Barre Syndrome Pipeline candidates-
A Significant contribution to the Guillain-Barre Syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Guillain-Barre Syndrome pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Guillain-Barre Syndrome condition and increased access to investments is encouraging growth of Guillain-Barre Syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Guillain-Barre Syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Guillain-Barre Syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Guillain-Barre Syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Guillain-Barre Syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Guillain-Barre Syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Guillain-Barre Syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Guillain-Barre Syndrome Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Guillain-Barre Syndrome drugs
- Late phase: Phase 3 and in-approval Guillain-Barre Syndrome drugs
- Company overview
- Snapshot
- Guillain-Barre Syndrome therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Guillain-Barre Syndrome- Disease Overview
2.2 Guillain-Barre Syndrome- Pipeline Snapshot
2.3 Guillain-Barre Syndrome- Pipeline Drugs by Phase
2.4 Guillain-Barre Syndrome- Pipeline Drugs by Company
2.5 Guillain-Barre Syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Akari Therapeutics Plc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.2 Annexon Inc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.3 Complement Pharma BV Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.4 CuraVac Inc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.5 Hansa Medical AB Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.6 Vitality Biopharma Inc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Guillain-Barre Syndrome- Phase 1 Drug Details
4.2 Guillain-Barre Syndrome- Phase 1 Drug Overview
4.3 Guillain-Barre Syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Guillain-Barre Syndrome- Phase 2 Drug Details
5.2 Guillain-Barre Syndrome- Phase 2 Drug Overview
5.3 Guillain-Barre Syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Guillain-Barre Syndrome- Phase 3 Drug Details
6.2 Guillain-Barre Syndrome- Phase 3 Drug Overview
6.3 Guillain-Barre Syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Guillain-Barre Syndrome- Pre-clinical Phase Drug Details
7.2 Guillain-Barre Syndrome- Pre-clinical Phase Drug Overview
7.3 Guillain-Barre Syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Guillain-Barre Syndrome- Disease Overview
2.2 Guillain-Barre Syndrome- Pipeline Snapshot
2.3 Guillain-Barre Syndrome- Pipeline Drugs by Phase
2.4 Guillain-Barre Syndrome- Pipeline Drugs by Company
2.5 Guillain-Barre Syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Akari Therapeutics Plc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.2 Annexon Inc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.3 Complement Pharma BV Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.4 CuraVac Inc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.5 Hansa Medical AB Guillain-Barre Syndrome Drug Pipeline, H2- 2019
3.6 Vitality Biopharma Inc Guillain-Barre Syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Guillain-Barre Syndrome- Phase 1 Drug Details
4.2 Guillain-Barre Syndrome- Phase 1 Drug Overview
4.3 Guillain-Barre Syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Guillain-Barre Syndrome- Phase 2 Drug Details
5.2 Guillain-Barre Syndrome- Phase 2 Drug Overview
5.3 Guillain-Barre Syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Guillain-Barre Syndrome- Phase 3 Drug Details
6.2 Guillain-Barre Syndrome- Phase 3 Drug Overview
6.3 Guillain-Barre Syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Guillain-Barre Syndrome- Pre-clinical Phase Drug Details
7.2 Guillain-Barre Syndrome- Pre-clinical Phase Drug Overview
7.3 Guillain-Barre Syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
